GlycoMimetics, Inc.

GlycoMimetics is a biopharmaceutical company dedicated to the design and development of small molecule therapies that mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule used to inhibit selectin types such as E-, P-, and L-selectins; and GMI-1051, a small molecule compound for the treatment or prevention of infections caused by Pseudomonas aeruginosa.